ProQR Therapeutics (PRQR) Assets Average (2014 - 2026)
ProQR Therapeutics (PRQR) posted Assets Average of $123.6 million for Q1 2026, down 10.64% sequentially from $138.3 million in Q4 2025, and down 27.09% YoY from $169.5 million in Q1 2025.
ProQR Therapeutics (PRQR) Assets Average (2014 - 2026) Analysis & Trends
ProQR Therapeutics has reported Assets Average for 12 years, with the latest figure at $123.6 million in Q1 2026.
- Quarterly Assets Average fell 27.09% year-over-year to $123.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $123.6 million (down 27.09% YoY) and the FY2025 annual result came in at $155.4 million, down 5.22% from the prior year.
- Assets Average fell to $123.6 million in Q1 2026 per PRQR's latest filing, from $138.3 million in the prior quarter.
- Over five years, Assets Average peaked at $226.6 million in Q1 2022 and troughed at $122.2 million in Q3 2024.
- A 5-year average of $156.7 million and a median of $151.5 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average tumbled 99.63% in 2022, then gained 23.15% in 2025.
- Over 5 years, Assets Average stood at $148.8 million in 2022, then grew by 1.83% to $151.5 million in 2023, then dropped by 2.03% to $148.4 million in 2024, then retreated by 6.81% to $138.3 million in 2025, then decreased by 10.64% to $123.6 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $123.6 million, $138.3 million, and $150.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | ProQR Therapeutics | 206.80 Mn | 111.86 Mn | - | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 123.60 Mn |
| Dec 31, 2025 | 138.31 Mn |
| Sep 30, 2025 | 150.53 Mn |
| Jun 30, 2025 | 157.62 Mn |
| Mar 31, 2025 | 169.52 Mn |
| Dec 31, 2024 | 148.41 Mn |
| Sep 30, 2024 | 122.24 Mn |
| Jun 30, 2024 | 130.85 Mn |
| Mar 31, 2024 | 141.46 Mn |
| Dec 31, 2023 | 151.49 Mn |
| Sep 30, 2023 | 157.88 Mn |
| Jun 30, 2023 | 165.38 Mn |
| Mar 31, 2023 | 172.20 Mn |
| Dec 31, 2022 | 148.77 Mn |
| Sep 30, 2022 | 156.90 Mn |
| Jun 30, 2022 | 202.28 Mn |
| Mar 31, 2022 | 226.63 Mn |
| Dec 31, 2021 | 235.05 Mn |
| Sep 30, 2021 | 212.94 Mn |
| Jun 30, 2021 | 55.35 Bn |